NYLIM
ABMD

New York Life Investment Management’s Abiomed Inc ABMD Stock Holding History

New York Life Investment Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,269
Closed -$1.79M – 1212
2022
Q3 		$1.79M Sell
7,269
-4
-0.1% -$1.08K 0.02% 536
2022
Q2 		$1.8M Buy
+7,273
New +$1.96M 0.02% 535

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $14.7B AUM 42.39% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

New York Life Investment Management's ABMD Position: Q4 2022 in Review

New York Life Investment Management sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 7,269 shares — an estimated $1.79M sold.

New York Life Investment Management first reported a position in ABMD in Q2 2022 and held it in 2 quarters. The position peaked at $1.8M in Q2 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • New York Life Investment Management reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • New York Life Investment Management sold 7,269 Abiomed Inc shares in Q4 2022, an estimated $1.79M.
  • New York Life Investment Management first reported a position in Abiomed Inc in Q2 2022 and held it in 2 quarters.
  • New York Life Investment Management's Abiomed Inc position peaked at $1.8M in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on New York Life Investment Management's 13F filing for Q4 2022, filed 10 Feb 2023.